Beta-3 Adrenerjik Reseptör Agonisti Mirabegron’un İnsan Üreter Kontraktilitesi Üzerine In Vıtro Etkileri
View/ Open
Date
2021-08Author
Artykov, Meylis
xmlui.dri2xhtml.METS-1.0.item-emb
Acik erisimxmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Artykov, M., In Vitro Effects of Beta-3 Adrenergic Receptor Selective Agonist Mirabegron on Human Ureter, Hacettepe University Faculty of Medicine, Department of Urology, Thesis in Urology, Ankara, 2021. In recent years, studies conducted with human bladder and ureter tissue have shown the presence and distribution of β3-AR in these tissues. In these studies, further investigation of drugs targeting β3-AR
in clinical settings and their potential use in ureteral diseases was proposed. Aim of our study was to investigate the effects of Mirabegron on the human ureter. During the period of the study, the ureteral tissues obtained from the graft kidney ureters of the patients who underwent donor nephrectomy in the Urology clinic were transferred to the laboratory of the Pharmacology Department under appropriate conditions and organ bath experiments were carried out. Our findings show that Mirabegron suppresses ureteral activity in vitro. Mirabegron decreases the contraction frequency in a dose-dependent manner in isolated ureteral tissue strips showing spontaneous activity. Mirabegron decreases the force of contraction in a dose-dependent manner in isolated ureteral tissue strips showing spontaneous activity. Mirabegron reduces the contraction frequency in isolated ureteral tissue strips with activity in 10mM KCL medium. Mirabegron reduces the force of contraction in isolated ureteral tissue strips with activity in 10mM KCL medium.
xmlui.mirage2.itemSummaryView.Collections
xmlui.dri2xhtml.METS-1.0.item-citation
VancouverThe following license files are associated with this item: